TY - JOUR
T1 - Headache characteristics and burden from chronic migraine with medication overuse headache
T2 - Cross-sectional observations from the Medication Overuse Treatment Strategy trial
AU - on behalf of the MOTS Investigators
AU - Schwedt, Todd J.
AU - Hentz, Joseph G.
AU - Sahai-Srivastava, Soma
AU - Spare, Nicole M.
AU - Martin, Vincent T.
AU - Treppendahl, Christina
AU - Digre, Kathleen
AU - Bennett, Nathan L.
AU - Birlea, Marius
AU - Watson, David
AU - Murinova, Natalia
AU - Robert, Teri
AU - Dodick, David W.
N1 - Funding Information:
Within the last 2 years: has served as a consultant or on an advisory board for Alder, Allergan, Biohaven, Cipla, Click Therapeutics, Eli Lilly, Equinox, Lundbeck, Novartis, Promius, Teva, Weber & Weber, and XoC. He has stock options in Aural Analytics and Nocira. He has received research funding from American Migraine Foundation, Amgen, Henry Jackson Foundation, National Institutes of Health, Patient Centered Outcomes Research Institute, and the United States Department of Defense. He has received royalties from UpToDate. received research funding from the Patient‐Centered Outcomes Research Institute. has served as a paid speaker for Eli Lilly and Teva and received funding for a fellowship program from Allergan. has served as a consultant or on an advisory board for Allergan, Amgen, Biohaven, Lundbeck, Novartis, Supernus, and Teva. She has received research funding from the American Migraine Foundation. has served on advisory boards for Allergan, Biohaven, Eli Lilly, Impel, Lundbeck/Alder, and Theranica. He has been a paid speaker for Allergan, Amgen, Biohaven, Eli Lilly, and Teva. has served on advisory boards for Alder, Amgen/Novartis, electroCore, Eli Lilly, Impax Labs, Impel NeuroPharma, the National Headache Foundation, Pernix, Promius Pharma, Supernus Pharmaceuticals, and Teva Pharmaceutical Industries, Inc. She has consulted for Biohaven, Impel NeuroPharma, Pernix, Promius Pharma, Supernus, and Zosano. She has also received speaker honoraria from Allergan (now AbbVie), Amgen, the American Academy of Nurse Practitioners, Avanir Pharmaceuticals, Depomed, Inc., Iroko Pharmaceuticals, the National Headache Foundation, Nautilus Neurosciences, Inc., Novartis, Pernix Therapeutics Holdings, Inc., Promius Pharma, Rockpointe, the Southern Headache Society, Supernus Pharmaceutical, Teva Pharmaceutical Industries, Inc., Usher‐Smith Laboratories, and Zogenix, Inc. She has served as a Principal Investigator for pharmaceutical‐sponsored clinical trials including Alder, Allergan, Avanir, electroCore, Novartis, Teva, and Theranica. has received royalty payment from Springer and Elsevier for books. has served as a consultant, on an advisory board, as a speaker, and/or principle investigator for Allergan, Amgen, Biohaven, electroCore, Lilly, Lundbeck, Teva, Promius, and Supernus. He participated as a principle investigator in studies funded by the National Institute of Health and Patient Centered Outcomes Research Institute. has nothing to declare. has served on an advisory board for Eli Lilly. has nothing to declare. has received compensation from the Patient‐Centered Outcomes Research Institute for serving as co‐investigator of the MOTS trial. has received personal fees from Amgen, AEON, Autonomic Technologies, Axsome, Allergan, Alder BioPharmaceuticals, Biohaven, Clexio, Dr Reddy's Laboratories/Promius, Cerecin, Eli Lilly, eNeura, Neurolief, Novartis, Ipsen, Impel, Satsuma, Supernus, Theranica, Teva, Vedanta, WL Gore, Nocira, XoC, Zosano, Upjohn (Division of Pfizer), Pieris, Revance, Equinox, Salvia, Lundbeck. He has received speaking fees from Eli Lilly, Novartis Canada, Amgen, Lundbeck, and CME fees or royalty payments from HealthLogix, Medicom Worldwide, MedLogix Communications, Mednet, Miller Medical, PeerView, WebMD Health/Medscape, Chameleon, Academy for Continued Healthcare Learning, Universal Meeting Management, Haymarket, Global Scientific Communications, Global Life Sciences, Global Access Meetings, Catamount, UpToDate (Elsevier), Oxford University Press, Cambridge University Press, and Wolters Kluwer Health. He has stock options in Precon Health, Aural Analytics, Healint, Theranica, Second Opinion/Mobile Health, Epien, Nocira, Matterhorn, Ontologics, and King‐Devick Technologies. He is on the Board of Directors for Paranet North America, Precon Health, Epien, Matterhorn, Ontologics, and King‐Devick Technologies. He holds a patent: 17189376.1‐1466:vTitle: Botulinum Toxin Dosage Regimen for Chronic Migraine Prophylaxis without fee. He receives research funding from American Migraine Foundation, US Department of Defense, PCORI, Henry Jackson Foundation. He has received professional society fees or reimbursement for travel: American Academy of Neurology, American Brain Foundation, American Headache Society, American Migraine Foundation, International Headache Society, and Canadian Headache Society. Todd J. Schwedt Joseph G. Hentz Soma Sahai‐Srivastava Nicole M. Spare Vincent T. Martin Christina Treppendahl Kathleen Digre Nathan L. Bennett Marius Birlea David Watson Natalia Murinova Teri Robert David W. Dodick
Publisher Copyright:
© 2021 American Headache Society
PY - 2021/2
Y1 - 2021/2
N2 - Objective: To describe headache characteristics, medication use, disability, and quality of life in a large patient cohort from the United States who have chronic migraine (CM) and medication overuse headache (MOH). Methods: In all, 610 adult patients were enrolled into the Medication Overuse Treatment Strategy trial from 34 healthcare clinics, including headache specialty, general neurology, and primary care clinics. Descriptive statistics characterize baseline demographics, headache characteristics, medication use, disability (Headache Impact Test 6 [HIT-6] and Migraine Functional Impact Questionnaire [MFIQ]), pain interference (PROMIS Pain Interference), and quality of life (EQ-5D-5L). Relationships with headache frequency were assessed. Results: Mean age was 45 years (SD 13) and 531/608 (87.3%) were females. Mean headache days per 30 was 24.3 (SD 5.5), including 13.6 (SD 7.1) with moderate to severe headache. Daily headaches were reported by 36.1% (219/607) of patients. Acute headache medications were used on 21.5 (SD 7.5) per 30 days. The most commonly overused medications were simple analgesics (378/607, 62% of patients), combination analgesics (246/607, 41%), and triptans (128/607, 21%). HIT-6, MFIQ, PROMIS Pain Interference, and EQ-5D-5L scores demonstrated substantial negative impact from CM with MOH on patient functioning and quality of life. Higher headache frequency was associated with more moderate–severe headache days, more frequent acute headache medication use, greater headache-related disability, and lower quality of life. Only 272/606 (44.9%) were taking migraine preventive medication. Conclusions: CM with MOH is associated with a large burden on patients in the United States. Higher headache frequency is associated with greater impact on functioning, pain interference, and quality of life.
AB - Objective: To describe headache characteristics, medication use, disability, and quality of life in a large patient cohort from the United States who have chronic migraine (CM) and medication overuse headache (MOH). Methods: In all, 610 adult patients were enrolled into the Medication Overuse Treatment Strategy trial from 34 healthcare clinics, including headache specialty, general neurology, and primary care clinics. Descriptive statistics characterize baseline demographics, headache characteristics, medication use, disability (Headache Impact Test 6 [HIT-6] and Migraine Functional Impact Questionnaire [MFIQ]), pain interference (PROMIS Pain Interference), and quality of life (EQ-5D-5L). Relationships with headache frequency were assessed. Results: Mean age was 45 years (SD 13) and 531/608 (87.3%) were females. Mean headache days per 30 was 24.3 (SD 5.5), including 13.6 (SD 7.1) with moderate to severe headache. Daily headaches were reported by 36.1% (219/607) of patients. Acute headache medications were used on 21.5 (SD 7.5) per 30 days. The most commonly overused medications were simple analgesics (378/607, 62% of patients), combination analgesics (246/607, 41%), and triptans (128/607, 21%). HIT-6, MFIQ, PROMIS Pain Interference, and EQ-5D-5L scores demonstrated substantial negative impact from CM with MOH on patient functioning and quality of life. Higher headache frequency was associated with more moderate–severe headache days, more frequent acute headache medication use, greater headache-related disability, and lower quality of life. Only 272/606 (44.9%) were taking migraine preventive medication. Conclusions: CM with MOH is associated with a large burden on patients in the United States. Higher headache frequency is associated with greater impact on functioning, pain interference, and quality of life.
KW - clinical trial
KW - disability
KW - headache
KW - medication overuse
KW - migraine
UR - http://www.scopus.com/inward/record.url?scp=85099199777&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099199777&partnerID=8YFLogxK
U2 - 10.1111/head.14056
DO - 10.1111/head.14056
M3 - Article
C2 - 33432635
AN - SCOPUS:85099199777
SN - 0017-8748
VL - 61
SP - 351
EP - 362
JO - Headache
JF - Headache
IS - 2
ER -